Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Q2 Revenues Flat, Losses Narrow

NEW YORK, July 29 - Sequenom reported flat revenues for the second quarter today, amid narrowed net losses.

The San Diego company had revenues of $7.7 million for the quarter, compared to revenues of $7.7 million for the same period last year.


R&D expenses came to $6.5 million, compared to $8.1 million for the year-ago quarter.


The company's net loss narrowed to $9.3 million, from $15 million in the second quarter of 2002.


As of June 30, Sequenom had $82.9 million in cash, cash equivalents, short-term investments, and restricted cash.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.